Open-label Trial of Leukine in Active Crohn's Disease

Stopped early · Phase 2

Conditions studied: Crohn Disease

In brief

The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.

Key facts

Study ID

NCT00206700

Run by

Genzyme, a Sanofi Company

People needed

378

Starts

2003-02-01

Expected to finish

2006-12-01

Last updated by the study team

2013-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide informed consent
• Participated in a previous study of sargramostim in Crohn's disease within the past 12 months
• Subjects who participated in protocols excluding concomitant steroid use:
• Must have moderately to severely active Crohn's disease at time of screening (CDAI score >/= 220 points and less than or equal to 475 points)
• Must be receiving less than or equal to 40 mg prednisone (or equivalent) daily at time of screening if treated with corticosteroids between completing their previous sargramostim study and entry into this study and be able to taper to less than or equal to 7.5 mg daily within one treatment cycle
• Subjects who participated in Protocol 307501
• Must have active Crohn's disease (CDAI score > 150 points and less than or equal to 450 points) if completely withdrawn from CS use
• Must be receiving less than or equal to 40 mg prednisone (or equivalent) daily at time of screening, be able to taper to less than or equal to 7.5 mg daily within 2 treatment cycles, and have a CDAI score less than or equal to 450 points if not completely withdrawn from CS use
• Have a negative serum pregnancy test within 2 weeks prior to receiving initial dose of sargramostim in female subjects of child-bearing potential (optional - may be waived by the investigator if the subject has had no interruption in contraception method since participation in the previous study)
• Agree to use of an adequate method of contraception throughout the study period for sexually-active males and females of childbearing potential
• Able to self-inject sargramostim or have a designee who can do so
• Able to comply with protocol requirements
• Have a negative stool exam if subject received a course of antibiotics since participation in the previous study

You may not qualify if…

• Pregnant or breastfeeding female
• Need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
• Gastrointestinal surgery within the prior 6 months
• Symptoms of bowel obstruction or confirmed evidence of a clinically-significant stricture within the last 6 months that has not been surgically corrected
• Serum creatinine greater than or equal to 2.0 mg/dL
• Alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin greater or equal to 2X the upper limit of normal; hemoglobin (Hb) < 8.0 gm/dL; platelet count greater than or equal to 800,000/mL; ANC less than or equal to 1,000/µL or > 20,000/µL (the exclusion of subjects with ANC > 20,000/µL applies only to entry into the first treatment cycle)
• Use of licensed/registered anti-tumor necrosis factor (TNF) therapy such as infliximab within 8 weeks prior to first dose of study drug in this trial
• Use of any of the following medications within 4 weeks prior to receiving the first dose of study drug: 6-mercaptopurine, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide
• Use of any experimental agent in a clinical trial since participating in a sargramostim trial
• History of allergy to yeast products or sargramostim
• Psychiatric illness or substance abuse that would interfere with ability to comply with protocol requirements or give informed consent
• Clinically important primary disease unrelated to Crohn's disease
• Prior exposure to natalizumab (Tysabri)

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Berkeley, California, United States
• Study site — Los Angeles, California, United States
• Study site — Orange, California, United States
• Study site — San Francisco, California, United States
• Study site — San Francisco, California, United States
• Study site — Tarzana, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Englewood, Colorado, United States
• Study site — Lakewood, Colorado, United States
• Study site — Littleton, Colorado, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Boca Raton, Florida, United States
• Study site — Clearwater, Florida, United States
• Study site — Gainesville, Florida, United States
• Study site — Gainesville, Florida, United States
• Study site — Hollywood, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — North Miami Beach, Florida, United States
• Study site — Winter Park, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.